Beckman Coulter and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, have announced expansion of their long-term partnership to include a global distribution agreement forScopio’s Full-Field Bone Marrow Aspirate (FF-BMA) application.
Bone marrow aspirate analysis is a vital procedure providing essential information for the assessment of various haematologic diseases. By aspirating a small sample of the liquid portion of bone marrow, clinicians can examine the cellular composition, as well as the morphology and maturity of the blood cells morphology. However, traditional BMA analysis uses manual, labour-intensive, time-consuming methods that are heavily reliant on highly skilled haematopathologists to ensure accuracy.
Scopio’s FF-BMA Application transforms BMA analysis by combining high-resolution Full-Field imaging with a robust AI-powered decision support system into a fully digital workflow seamlessly integrated with Scopio’s X100 and X100HT scanners. It also enables haematopathologists to review bone marrow smears remotely (via a secure hospital network), potentially reducing turnaround time, fostering collaboration, facilitating second opinions, and bolstering diagnostic confidence.
Scopio’s X100 / X100HT with FF-BMA application is CE-Marked.
“In today’s laboratory , there is limited technology available to assist in the analysis of bone marrow aspirate,” said Chris Hagen, Senior Vice President and General Manager, Core Lab Specialty Products for Beckman Coulter Diagnostics. “With Scopio’s technology, scientists can assess hundreds of cells to evaluate morphological features with the support of artificial intelligence using the world’s first BMA digital imaging and analysis solutions. Reviewers can observe representative cell distribution across the sample at rates far exceeding that of reviews done by manual microscopes. We are thrilled to expand our partnership with Scopio and continue to bring full-field, AI-powered, digital-imaging innovations to clinical laboratories worldwide.”
“We are excited to extend our global partnership agreement with Beckman Coulter, which exemplifies our shared mission to advance the digital transformation of clinical laboratories around the world,” said Itai Hayut, CEO and Co-Founder of Scopio Labs. “The addition of our first-of-its-kind digital bone marrow application into Beckman Coulter’s haematology offering, signifies a strong endorsement of the successful adoption of Scopio's Full-Field digital cell morphology platform in the market to date. We look forward to continuing our partnership as Scopio brings new products to the market to fulfil the potential of haematology diagnostics in this new digital era.”
Since 2022, Beckman Coulter and Scopio have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio’s X100 and X100HT digital cell morphology platforms employ full-field imaging and AI decision support eliminating the need for manual microscopy, while providing laboratory scientists and physicians true workflow benefits with simple to use remote viewing through a secured network.
In 2023, Beckman Coulter Diagnostics announced a new end-to-end automated haematology solution by connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with the Scopio X100HT high-throughput digital cell morphology platform, complete with digitalised, AI-assisted peripheral blood smear analysis.
To learn more, visit www.scopiolabs.com.